Open Access

Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure

  • Andreas Walker1,
  • Sandra Filke2,
  • Nadine Lübke1,
  • Martin Obermeier3,
  • Rolf Kaiser4,
  • Dieter Häussinger2,
  • Jörg Timm1Email author and
  • Hans H. Bock2
Virology Journal201714:106

https://doi.org/10.1186/s12985-017-0779-4

Received: 1 February 2017

Accepted: 6 June 2017

Published: 8 June 2017

Abstract

Background

The major resistance-associated substitution for sofosbuvir (S282T) in HCV NS5B causes severe viral fitness costs and rapidly reverts back to prototype in the absence of selection pressure. Accordingly, resistance against sofosbuvir is rarely detected even in patients after treatment failure.

Case presentation

We report a case of a GT3a infected patient with viral breakthrough under SOF/DCV therapy. At the time of breakthrough the RAS S282T was predominant in NS5B and then rapidly disappeared during follow-up by week 12 after treatment. Interestingly, despite only serine was encoded in position 282 during follow-up, two distinct genetic pathways for reversion were detectable. In 31% of the quasispecies the original codon for serine was present whereas in the majority of the quasispecies an alternative codon was selected. This alternative codon usage was unique for all GT3a isolates from the HCV database and remained detectable as a genetic footprint for prior resistance selection at the RNA level for at least 6 months.

Conclusions

Comparative analyses of viral sequences at the codon level before and after DAA treatment may help to elucidate the patient’s history of resistance selection, which is particularly valuable for highly unfit substitutions that are detectable only for a short period of time. If such codon changes increase the risk of re-selection of resistance upon a second exposure to SOF remains to be addressed.

Keywords

Sofosbuvir Daclatasvir Resistance Genotype 3a Breakthrough S282T MEDCOAT

Background

During the last few years, several directly acting antivirals (DAAs) became available for treatment of chronic hepatitis C, starting a new era of therapy of hepatitis C virus (HCV) infection. DAAs were typically optimized for inhibition of viral replication of HCV genotype 1a and 1b and are in most cases less active against genotype 3a. Currently, only a combination of the nucleoside analogue sofosbuvir (SOF) and one of the NS5A inhibitors Velpatasvir (VEL) or daclatasvir (DCV) are recommended for treatment of patients infected with HCV genotype 3a [1]. Depending on the fibrosis stage, prior treatment experience and the duration of therapy, sustained viral response rates (SVR) between 63 and 96% have been reported [2, 3]. In clinical studies resistance-associated substitutions (RAS) were detected in the majority of patients who failed to achieve SVR (reviewed in [4, 5]). In Genotype 3a the most common NS5A-RAS are Y93H, A30K and L31I [6]. In the ALLY-3 trial NS5A-Y93H RAS was present in 15 of 16 patients with relapse, whereas NS5B RASs associated with resistance to SOF (aa159, 282, or 321) were not detected [2]. Up to date the major SOF resistance associated substitution S282T was only found in few patients with viral relapse [79].

Case presentation

We report here a case of a GT3a infected treatment naïve patient with viral breakthrough under SOF/DCV therapy. The patient was a 59 year old non-cirrhotic, HIV-negative woman treated at the University Hospital Düsseldorf, Germany. In accordance with the German and international guidelines treatment was initiated with 400 mg Sofosbuvir and 60 mg Daclatasvir once daily. Viral load at baseline was 562.530 IU/ml and dropped below the detection limit (<15 IU/ml) at week 4 (Fig. 1). Two days prior to the end of treatment at week 12 HCV-RNA was detectable again at low levels (493 IU/ml) consistent with a viral breakthrough. During follow-up 12 weeks after the end of treatment viral load further increased to high levels (5.290.000 IU/ml). Notably, due to difficulties with swallowing of tablets the patient had used MEDCOAT® tablet coating for assistance. Plasma drug levels at week 4 and at breakthrough were 182 ng/ml and 306 ng/ml for DCV and 256 ng/ml and 375 ng/ml for the SOF metabolite GS-331007 (Fig. 1). Amplicon sequencing [10] and resistance phenotyping using Geno2Pheno [HCV] (http://hcv.bioinf.mpi-inf.mpg.de/index.php; [11]) showed no RAS in NS5A and NS5B at baseline. Resistance testing at week 12 (day 82), when the patient was still under treatment, revealed the RAS S282T in NS5B and Y93H in NS5A (Fig. 1). Y93H persisted in 68.5% of the quasispecies during follow-up at week 12 and continued to revert back to nearly undetectable levels at follow-up at week 24. The substitution S282T had already fully reverted back to prototype at follow-up at week 12 consistent with severe fitness costs associated with this RAS. Interestingly, two distinct pathways were selected for reversion to the prototype residue. Ultra-deep sequencing revealed that 31% of the quasispecies reverted back to the original codon for serine (AGT) whereas in 68% of the quasispecies an alternative codon for serine (TCT) was selected. This alternative codon usage was unique and was absent from 114 GT3a isolates analyzed in our laboratory and from all 489 reference sequences from the HCV database. In line with negative selection of alternative codon usage in this position, the frequency of variants in the quasispecies utilizing the alternative codon further decreased to 24.2% during follow up at week 24.
Fig. 1

Therapy failure of a patient with HCV GT3a infection treated with SOF/DCV for 12 weeks. a HCV viral load (black line), time of treatment (gray box) and plasma drug levels for DCV (white bar) and the SOF metabolite GS-331007 (black bar) are shown. b Frequency of the RAS NS5A-Y93H and NS5B-S282T at baseline (BL), end of treatment (week 12) and follow-up (FU). c Codon usage at NS5B position 282 as determined by ultra-deep sequencing

Discussion and conclusions

We report here, to our knowledge, the first case of selection of the RAS S282T in a patient infected with genotype GT3a. Selection of the RAS was associated with a viral breakthrough detected at week 12, when the plasma drug levels were in a low therapeutic range. If the low plasma drug levels are a consequence of the MEDCOAT® coating of the tablets is unknown since no peer reviewed data on the pharmacokinetics are available. However, it has been described that co-medication with proton pump inhibitors (PI) during HCV-treatment is a risk factor for treatment failure [12]. Accordingly, it seems plausible that the usage of MEDCOAT® might be a risk factor for treatment failure as well.

Although reversion of NS5A RAS has been described, in the majority (85–94%) of genotype 1 infected patients NS5A RAS persist in the viral population over years after treatment [1315]. For genotype 3a no systematic analysis of the destiny of NS5A RAS after treatment failure is available. In line with previous reports the S282T substitution rapidly reverted back to prototype by week 12 after treatment [5]. Interestingly, despite only serine was encoded in position 282 at that time, the codon usage had changed leaving a detectable genetic footprint of prior resistance selection that was unique for GT3a isolates. This genetic footprint of prior resistance selection remained detectable at the RNA level for at least 6 months, consistent with lower fitness costs compared to the original RAS. We conclude that comparative analyses of viral sequences at the codon level before and after DAA treatment may help to elucidate the patient’s history of resistance selection, which is particularly valuable for highly unfit RAS that are detectable only for a short period of time. If such codon changes increase the risk of re-selection of resistance upon a second exposure to SOF is unknown. The patient reported here was not re-treated until now, as no advanced fibrosis was yet detectable.

Abbreviations

DCV: 

Daclatasvir

HCV: 

Hepatitis C Virus

RAS: 

resistance-associate substitution

SOF: 

Sofosbuvir

Declarations

Acknowledgements

We thank Iris Herrmann and Jennifer Camdereli for excellent technical help.

Funding

This work was funded by DFG grant TI 323/4–1

Availability of data and materials

The datasets used and analyzed in the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Acquisition of data (AW, SF, NL, MO, RK, JT), study concept and design (DH, JT, HB), analysis and interpretation of data (AW, NL, JT, HB), drafting of the manuscript (AW, JT, HB) critical revision of the manuscript (AW, SF, NL, MO, RK, DH, JT,HB), study supervision (JT,DH,HB). All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Obtained from the patient.

Ethics approval and consent to participate

Informed consent was obtained from the patient, and the study protocol was approved by the ethics committee of the Medical Faculty of the University of Düsseldorf (Ethic #2012048) in accordance with the guidelines of the Declaration of Helsinki.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute for Virology, Heinrich-Heine-University, University Hospital
(2)
Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University, University Hospital
(3)
Medical Center for Infectious Diseases (MIB)
(4)
Institute of Virology, University of Cologne

References

  1. European Association for the Study of the Liver. Electronic address, e.e.e., EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153–94. PMID: 27667367.Google Scholar
  2. Nelson DR, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–35.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12(5):284–92.View ArticlePubMedGoogle Scholar
  4. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70-86. PMID: 27080301.Google Scholar
  5. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.View ArticlePubMedGoogle Scholar
  6. Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57(1):13–8.View ArticlePubMedGoogle Scholar
  7. Donaldson EF, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61(1):56–65.View ArticlePubMedGoogle Scholar
  8. Hedskog C, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22(11):871–81.View ArticlePubMedGoogle Scholar
  9. Svarovskaia ES, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59(12):1666–74.View ArticlePubMedGoogle Scholar
  10. Walker A, et al. Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany. J Clin Virol. 2015;70:43–5.View ArticlePubMedGoogle Scholar
  11. Kalaghatgi P, et al. Geno2pheno[HCV] - a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One. 2016;11(5):e0155869.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Tapper EB, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893–9.View ArticlePubMedGoogle Scholar
  13. Dvory-Sobol H, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol. 2015;62(Suppl 2):S221.View ArticleGoogle Scholar
  14. Krishnan P, et al. O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015;62(Suppl 2):S220.Google Scholar
  15. McPhee F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58(3):902–11.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement